Germany · Delayed Price · Currency is EUR Healios K.K. Company Description
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of solid tumors.
It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
| Country | Japan |
| Founded | 2011 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 65 |
| CEO | Tadahisa S. Kagimoto |
Contact Details
Address: Hibiya Mitsui Tower Chiyoda, 100-0006 Japan | |
| Phone | 81 3 4590 8006 |
| Website | healios.co.jp |
Stock Details
| Ticker Symbol | 6VX |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tadahisa S. Kagimoto | Chief Executive Officer |
| Richard P. Kincaid | Chief Financial Officer |